Molecular pathogenesis of fungal infections

Principles of Molecular Medicine

Volumn , Issue , 2006, Pages 920-933

  Segal, Brahm H ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antifungal agents; Aspergillus; Candida; Cryptococcus; dimorphic fungi; drug development; genomics; vaccine; virulence factors

Indexed keywords

EID: 84857918205     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-963-9_95     Document Type: Chapter

References (176)

1. Abuodeh RO, Shubitz LF, Siegel E, et al. Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infect Immun 1999;67:2935-2940.
2. Agarwal AK, Rogers PD, Baerson SR, et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003;278:34,998-35, 015. Epub 2003 Jun 24.
3. Alberti-Segui C, Morales AJ, Xing H, et al. Identification of potential cellsurface proteins in Candida albicans and investigation of the role of a putative cell-surface glycosidase in adhesion and virulence. Yeast 2004;21:285-302.
4. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40(Suppl 6):S414-S421.
5. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in primary immunodeficiencies. Med Mycol Supplement 2005;43:S247-S259.
6. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-1324.
7. Bammert GF, Fostel JM. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob Agents Chemother 2000;44:1255-1265.
8. Belanger PH, Johnston DA, Fratti RA, Zhang M, Filler SG. Endocytosis of Candida albicans by vascular endothelial cells is associated with tyrosine phosphorylation of specific host cell proteins. Cell Microbiol 2002;4:805-812.
9. Birch M, Denning DW, Robson GD. Comparison of extracellular phospholipase activities in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 2004;42:81-86.
10. Birch M, Robson G, Law D, Denning DW. Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun 1996;64:751-755.
11. Blankenship JR, Wormley FL, Boyce MK, et al. Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell 2003;2:422-430.
12. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91:1979-1986.
13. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 1998;28: 543-554.
14. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-2261.
15. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-366. Epub 2002 Jul 25.
16. Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002;4:1281-1290.
17. Brandhorst TT,Wuthrich M,Warner T, Klein B. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J Exp Med 1999;189:1207-1216.
18. Brown AJ, Gow NA. Regulatory networks controlling Candida albicans morphogenesis. Trends Microbiol 1999;7:333-338.
19. Buurman ET, Westwater C, Hube B, Brown AJ, Odds FC, Gow NA. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci USA 1998;95:7670-7675.
20. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1:17-24.
21. Casadevall A, Steenbergen JN, Nosanchuk JD. 'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi- the Cryptococcus neoformans paradigm. Curr Opin Microbiol 2003;6:332-337.
22. Casadevall A, Cleare W, Feldmesser M, et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998;42:1437-1446.
23. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(Suppl 6):S392-S400.
24. Chang YC, Segal BH, Holland SM, Miller GF, Kwon-Chung KJ. Virulence of catalase-deficient aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J Clin Invest 1998;101:1843-1850.
25. Chiou CC, Mavrogiorgos N, Tillem E, Hector R,Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001;45: 3310-3321.
26. Cole GT, Zhu SW, Hsu LL, Kruse D, Seshan KR, Wang F. Isolation and expression of a gene which encodes a wall-associated proteinase of Coccidioides immitis. Infect Immun 1992;60:416-427.
27. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005;309:2185-2189.
28. Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev 2004;17:804-839.
29. Cruz MC, Fox DS, Heitman J. Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. Embo J 2001;20:1020-1032.
30. Davis D, Edwards JE Jr., Mitchell AP, Ibrahim AS. Candida albicans RIM101 pH response pathway is required for host-pathogen interactions. Infect Immun 2000;68:5953-5959.
31. De Bernardis F, Tacconelli E, Mondello F, et al. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunol Med Microbiol 2004;41:27-34.
32. De Lucca AJ, Walsh TJ. Antifungal peptides: Novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999;43:1-11.
33. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-615.
34. Dennis CG, Greco WR, Brun Y, et al. The effect of combination amphotericin b and micafungin on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50:422-427.
35. Dromer F, Charreire J, Contrepois A, Carbon C,Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987;55:749-752.
36. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three- year analysis. Clin Infect Dis 1999;29:239-244.
37. Falkow S. Molecular Koch's postulates applied to microbial pathogenicity. Rev Infect Dis 1988;10(Suppl 2):S274-S276.
38. Finkel-Jimenez B, Wuthrich M, Klein BS. BAD1, an essential virulence factor of Blastomyces dermatitidis, suppresses host TNF-alpha production through TGF-beta-dependent and -independent mechanisms. J Immunol 2002;168:5746-5755.
39. Fleuridor R, Zhong Z, Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 1998;178:1213-1216.
40. Fratti RA, Belanger PH, Ghannoum MA, Edwards JE Jr., Filler SG. Endothelial cell injury caused by Candida albicans is dependent on iron. Infect Immun 1998;66:191-196.
41. Frey CL, Drutz DJ. Influence of fungal surface components on the interaction of Coccidioides immitis with polymorphonuclear neutrophils. J Infect Dis 1986;153:933-943.
42. Fries BC, Goldman DL, Cherniak R, Ju R, Casadevall A. Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun 1999;67:6076-6083.
43. Fu Y, Ibrahim AS, Sheppard DC, et al. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 2002;44:61-72.
44. Gallin JI, Alling DW, Malech HL, et al. Itraconazole prophylaxis for fungal infections in chronic granulomatous disease of childhood. N Engl J Med 2003;348:2416-2422.
45. Ganendren R,Widmer F, Singhal V,Wilson C, Sorrell T,Wright L. In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:1561-1569.
46. Garcia-Rivera J, Casadevall A. Melanization of Cryptococcus neoformans reduces its susceptibility to the antimicrobial effects of silver nitrate. Med Mycol 2001;39:353-357.
47. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420:182-186.
48. Gaziano R, Bozza S, Bellocchio S, et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004;48:4414-4421.
49. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-351.
50. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000;13:122-143.
51. Giusani AD, Vinces M, Kumamoto CA. Invasive filamentous growth of Candida albicans is promoted by Czf1p-dependent relief of Efg1pmediated repression. Genetics 2002;160:1749-1753.
52. Goldman DL, Fries BC, Franzot SP, Montella L, Casadevall A. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci USA 1998;95: 14,967-14,972.
53. Gomez BL, Nosanchuk JD. Melanin and fungi. Curr Opin Infect Dis 2003;16:91-96.
54. Green CB, Cheng G, Chandra J, Mukherjee P, Ghannoum MA, Hoyer LL. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 2004;150:267-275.
55. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15-19.
56. Hanel H, Kirsch R, Schmidts HL, Kottmann H. New systematically active antimycotics from the beta-blocker category. Mycoses 1995;38:251-264.
57. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
58. Heymann P, Gerads M, Schaller M, Dromer F, Winkelmann G, Ernst JF. The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun 2002;70:5246-5255.
59. Hissen AH, Chow JM, Pinto LJ, Moore MM. Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores. Infect Immun 2004;72:1402-1408.
60. Hogan LH, Josvai S, Klein BS. Genomic cloning, characterization, and functional analysis of the major surface adhesin WI-1 on Blastomyces dermatitidis yeasts. J Biol Chem 1995;270:30,725-30,732.
61. Hoyer LL. The ALS gene family of Candida albicans. Trends Microbiol 2001;9:176-180.
62. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, Edwards JE Jr. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005;73: 999-1005.
63. Ibrahim AS, Mirbod F, Filler SG, et al. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect Immun 1995;63:1993-1998.
64. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743-746. Epub 2004 Aug 13.
65. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-808.
66. Jiang B, Bussey H, Roemer T. Novel strategies in antifungal lead discovery. Curr Opin Microbiol 2002;5:466-471.
67. Jiang C, Magee DM, Ivey FD, Cox RA. Role of signal sequence in vaccine- induced protection against experimental coccidioidomycosis. Infect Immun 2002;70:3539-3545.
68. Johnson SM, Kerekes KM, Zimmermann CR,Williams RH, Pappagianis D. Identification and cloning of an aspartyl proteinase from Coccidioides immitis. Gene 2000;241:213-222.
69. Jones T, Federspiel NA, Chibana H, et al. The diploid genome sequence of Candida albicans. Proc Natl Acad Sci USA 2004;101:7329-7334. Epub 2004 May 3.
70. Kogan TV, Jadoun J, Mittelman L, Hirschberg K, Osherov N. Involvement of secreted Aspergillus fumigatus proteases in disruption of the actin fiber cytoskeleton and loss of focal adhesion sites in infected A549 lung pneumocytes. J Infect Dis 2004;189:1965-1973. Epub 2004 May 11.
71. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: A case control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360.
72. Kraus PR, Heitman J. Coping with stress: calmodulin and calcineurin in model and pathogenic fungi. Biochem Biophys Res Commun 2003;311:1151-1157.
73. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004;5:186-197.
74. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-1780.
75. Kunert J, Kopecek P. Multiple forms of the serine protease Alp of Aspergillus fumigatus. Mycoses 2000;43:339-347.
76. Larsen RA, Pappas PG, Perfect J, et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005;49:952-958.
77. Leidich SD, Ibrahim AS, Fu Y, et al. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 1998;273:26,078-26,086.
78. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.
79. Li F, Palecek SP. EAP1, a Candida albicans gene involved in binding human epithelial cells. Eukaryot Cell 2003;2:1266, 1267.
80. Li M, Martin SJ, Bruno VM, Mitchell AP, Davis DA. Candida albicans Rim13p, a protease required for Rim101p processing at acidic and alkaline pHs. Eukaryot Cell 2004;3:741-751.
81. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997;90: 939-949.
82. Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: Internalization, injury, and stimulation of tissue factor activity. Blood 2004;103:2143-2149. Epub 2003 Nov 20.
83. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39: 1563-1571. Epub 2004 Nov 9.
84. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002;277:39,320-39,326.
85. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39: 797-802. Epub 2004 Aug 27.
86. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
87. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-952.
88. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-647. Epub 2001 Jul 30.
89. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
90. Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillusinduced activation of murine macrophages. Cell Microbiol 2003;5: 561-570.
91. Mohagheghpour N, Waleh N, Garger SJ, Dousman L, Grill LK, Tuse D. Synthetic melanin suppresses production of proinflammatory cytokines. Cell Immunol 2000;199:25-36.
92. Monod M, Togni G, Hube B, Sanglard D. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol 1994; 13:357-368.
93. Monod M, Capoccia S, Lechenne B, Zaugg C, Holdom M, Jousson O. Secreted proteases from pathogenic fungi. Int J Med Microbiol 2002; 292:405-419.
94. Monod M, Paris S, Sanglard D, Jaton-Ogay K, Bille J, Latge JP. Isolation and characterization of a secreted metalloprotease of Aspergillus fumigatus. Infect Immun 1993;61:4099-4104.
95. Monod M, Paris S, Sarfati J, Jaton-Ogay K, Ave P, Latge JP. Virulence of alkaline protease-deficient mutants of Aspergillus fumigatus. FEMS Microbiol Lett 1993;106:39-46.
96. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347: 2020-2029.
97. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992;60: 4534-4541.
98. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Differential expression of Candida albicans phospholipase B (PLB1) under various environmental and physiological conditions. Microbiology 2003a;149: 261-267.
99. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003b;71: 4333-4340.
100. Mukherjee PK, Seshan KR, Leidich SD, Chandra J, Cole GT, Ghannoum MA. Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 2001;147:2585-2597.
101. Mullbacher A, Eichner RD. Immunosuppression in vitro by a metabolite of a human pathogenic fungus. Proc Natl Acad Sci USA 1984;81:3835-3837.
102. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: Review of 342 cases. Chest 1998;114: 251-262.
103. Naglik JR, Rodgers CA, Shirlaw PJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003;188:469-479. Epub 2003 Jul 14.
104. Narasipura SD, Ault JG, Behr MJ, Chaturvedi V, Chaturvedi S. Characterization of Cu,Zn superoxide dismutase (SOD1) gene knockout mutant of Cryptococcus neoformans var. gattii: role in biology and virulence. Mol Microbiol 2003;47:1681-1694.
105. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185:1483-1489.
106. Netea MG, Warris A, Van der Meer JW, et al. Aspergillus fumigatus evades immune recognition during germination through loss of tolllike receptor-4-mediated signal transduction. J Infect Dis 2003;188: 320-326.
107. Newman SL, Chaturvedi S, Klein BS. The WI-1 antigen of Blastomyces dermatitidis yeasts mediates binding to human macrophage CD11b/CD18 (CR3) and CD14. J Immunol 1995;154:753-761.
108. Noverr MC, Cox GM, Perfect JR, Huffnagle GB. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun 2003;71:1538-1547.
109. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004;38:1237-1242. Epub 2004 Apr 15.
110. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998;42:282-288.
111. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. Embo J 1997;16:2576-2589.
112. Okumura Y, Ogawa K, Nikai T. Elastase and elastase inhibitor from Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger. J Med Microbiol 2004;53:351-354.
113. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003;37:415-425. Epub 2003 Jul 22.
114. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97:13,766-13,771.
115. Pahl HL, Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med 1996;183:1829-1840.
116. Pappagianis D. Evaluation of the protective efficacy of the killed Coccidiodes immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 1993;148:656-660.
117. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-260.
118. Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000;2:22-28.
119. Penalva MA, Arst HN Jr. Regulation of gene expression by ambient pH in filamentous fungi and yeasts. Microbiol Mol Biol Rev 2002;66: 426-446.
120. Pendrak ML, Yan SS, Roberts DD. Sensing the host environment: recognition of hemoglobin by the pathogenic yeast Candida albicans. Arch Biochem Biophys 2004;426:148-156.
121. Peng T, Shubitz L, Simons J, Perrill R, Orsborn KI, Galgiani JN. Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infection with Coccidioides immitis in mice. Infect Immun 2002;70:3330-3335.
122. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40(Suppl 6):S401-S408.
123. Popolo L, Gilardelli D, Bonfante P, Vai M. Increase in chitin as an essential response to defects in assembly of cell wall polymers in the ggp1delta mutant of Saccharomyces cerevisiae. J Bacteriol 1997;179:463-469.
124. Ramanan N, Wang Y. A high-affinity iron permease essential for Candida albicans virulence. Science 2000;288:1062-1064.
125. Ramon AM, Porta A, Fonzi WA. Effect of environmental pH on morphological development of Candida albicans is mediated via the PacC-related transcription factor encoded by PRR2. J Bacteriol 1999;181: 7524-7530.
126. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002;416: 291-297.
127. Rhodes JC, Oliver BG, Askew DS,Amlung TW. Identification of genes of Aspergillus fumigatus up-regulated during growth on endothelial cells. Med Mycol 2001;39:253-260.
128. Riggle PJ, Andrutis KA, Chen X, Tzipori SR, Kumamoto CA. Invasive lesions containing filamentous forms produced by a Candida albicans mutant that is defective in filamentous growth in culture. Infect Immun 1999;67:3649-3652.
129. Ringden O. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. J Antimicrob Chemother 2002;49(Suppl 1):51-55.
130. Ripeau JS, Fiorillo M, Aumont F, Belhumeur P, de Repentigny L. Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. J Infect Dis 2002;185:1094-1102. Epub 2002 Mar 21.
131. Rogers PD, Barker KS. Evaluation of differential gene expression in fluconazole- susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob Agents Chemother 2002;46: 3412-3417.
132. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
133. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239. Epub 2004 Feb 24.
134. Rosas AL, Casadevall A. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett 1997;153:265-272.
135. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 1996;184:377-386.
136. San-Blas G, Travassos LR, Fries BC, et al. Fungal morphogenesis and virulence. Med Mycol 2000;38:79-86.
137. Sanchez AA, Johnston DA, Myers C, Edwards JE Jr., Mitchell AP, Filler SG. Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect Immun 2004;72:598-601.
138. Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 1990;58:1919-1923.
139. Santangelo R, Zoellner H, Sorrell T, et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun 2004;72:2229-2239.
140. Schofield DA,Westwater C,Warner T, Nicholas PJ, Paulling EE, Balish E. Hydrolytic gene expression during oroesophageal and gastric candidiasis in immunocompetent and immunodeficient gnotobiotic mice. J Infect Dis 2003;188:591-599. Epub 2003 Jul 24.
141. Segal BH, Holland SM. Invasive aspergillosis in chronic granulomatous disease. The Aspergillus website. http://www.aspergillus.man.ac.uk Jan. 26, 2006.
142. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000;79:170-200.
143. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease with invasive filamentous fungal infection. Clin Infect Dis 2005;40:1684-1688.
144. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005;159:181-188.
145. Sheppard DC, Yeaman MR, Welch WH, et al. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 2004;279:30,480-30,489. Epub 2004 May 5.
146. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001;166:4620-4626.
147. Silva AJ, Benitez JA. Th1-type immune response to a Coccidioides immitis antigen delivered by an attenuated strain of the non-invasive enteropathogen Vibrio cholerae. FEMS Immunol Med Microbiol 2005;43:393-398.
148. Silva AJ, Mohan A, Benitez JA. Cholera vaccine candidate 638: intranasal immunogenicity and expression of a foreign antigen from the pulmonary pathogen Coccidioides immitis. Vaccine 2003;21:4715-4721.
149. Spellberg BJ, Ibrahim AS, Avenissian V, et al. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 2005;73:6191-6193.
150. Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 1999;283:1535-1538.
151. Stanzani M, Orciuolo E, Lewis R, et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 2005;105:2258-2265. Epub 2004 Nov 16.
152. Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci USA 2001;98:15,245-15,250. Epub 2001 Dec 11.
153. Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004; 48:1664-1669.
154. Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004;38:1131-1136. Epub 2004 Apr 5.
155. Tauszig-Delamasure S, Bilak H, Capovilla M, Hoffmann JA, Imler JL. Drosophila MyD88 is required for the response to fungal and Grampositive bacterial infections. Nat Immunol 2002;3:91-97.
156. Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 2000;12: 201-210.
157. Tsunawaki S,Yoshida LS, Nishida S, Kobayashi T, Shimoyama T. Fungal metabolite gliotoxin inhibits assembly of the human respiratory burst NADPH oxidase. Infect Immun 2004;72:3373-3382.
158. Ullmann BD, Myers H, Chiranand W, et al. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell 2004;3: 715-723.
159. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-815.
160. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 2002;46:3394-3400.
161. Vecchiarelli A, Pietrella D, Lupo P, Bistoni F, McFadden DC, Casadevall A. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol 2003;74:370-378.
162. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation (see comments). J Infect Dis 1997;175: 1459-1466.
163. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004;10(Suppl 1):48-66.
164. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45: 3487-3496.
165. Wang Y, Casadevall A. Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol 1994a;60:3864-3866.
166. Wang Y, Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun 1994b;62:3004-3007.
167. Wang JE, Warris A, Ellingsen EA, et al. Involvement of CD14 and tolllike receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001;69:2402-2406.
168. Wasylnka JA, Moore MM. Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect Immun 2002;70: 3156-3163.
169. Wasylnka JA, Moore MM. Aspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells. J Cell Sci 2003; 116:1579-1587.
170. Weissman Z, Kornitzer D. A family of Candida cell surface haem-binding proteins involved in haemin and haemoglobin-iron utilization. Mol Microbiol 2004;53:1209-1220.
171. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-169.
172. Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr, Klein BS. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 2003;197:1405-1416.
173. Yamada A, Kataoka T, Nagai K. The fungal metabolite gliotoxin: Immunosuppressive activity on CTL-mediated cytotoxicity. Immunol Lett 2000;71:27-32.
174. Yoshida LS, Abe S, Tsunawaki S. Fungal gliotoxin targets the onset of superoxide-generating NADPH oxidase of human neutrophils. Biochem Biophys Res Commun 2000;268:716-723.
175. Yuen KY, Woo PC, Ip MS, et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997;25:37-42.
176. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR. Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun 2001;69:5589-5596.